Figure 4

Immunohistochemistry analyses of SV2B. (a) The age groups of 0–20 years and 61–80 years reached significant difference in expression of SV2B when compared to their normal counterparts (Normal Tissue versus Age 0–20, p < 0.0249; Adjacent Brain Tissue versus Age 0–20, p < 0.0344; Normal Tissue versus Age 61–80, p < 0.0200; Adjacent Brain Tissue versus Age 61–80, p < 0.0231). (b) Significantly higher levels of the protein were observed within glioblastomas when compared to astrocytoma, IDH-wildtype diffuse astrocytic tumors, and oligodendrogliomas (p ≪ 0.0001, p < 0.0056, and p ≪ 0.0001, respectively). Medulloblastoma samples also reached statistical significance of high abundance of SV2B in comparison to astrocytoma (p < 0.0245). (c) Significant differences between tumor grades 3 and 4 in comparison to normal brain tissue were observed (p < 0.0133 and p < 0.0002, respectively). Significant differences between grades 1 and 2 in comparison to grade 4, and grades 2 and 3 we also depicted (Grade 1 versus Grade 4, p < 0.0390; Grade 2 versus Grade 4, p < 0.0001; Grade 2 versus Grade 3, p < 0.0184). (d) Microscopic images of SV2B stained tissues sections illustrating the staining intensity within normal brain tissue, tumor adjacent tissue, and different brain malignancies at × 100 magnification. (e) Microscopic images of SV2B stained tissues cores of normal brain tissue, tumor adjacent tissue, and different brain malignancies at × 40 magnification. NT normal tissue, NAT normal adjacent tissue, AST astrocytoma, OLG oligodendroglioma, MB medulloblastoma, GBM glioblastoma, Ns non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.